Market Overview - The Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index closed up by 0.18%, 0.09%, and 0.71% respectively, with over 3,400 stocks declining and more than 1,900 stocks rising, totaling a trading volume of over 2.9 trillion [4]. Storage Sector - The storage chip sector experienced a significant rally, with Dongxin Technology and Huada Technology hitting the daily limit, while Puran Technology, Hengsuo Technology, and Jingzhida rose over 10%. Memory and flash memory prices increased by 4.27% and 3.92% respectively [7][8]. - The surge in the storage sector was attributed to a "breaking news" regarding SK Hynix's exclusive supply of HBM3E chips to Microsoft's Maia 200, which is expected to drive demand [8][9]. Nipah Virus Impact - The Nipah virus gained attention, leading to a rebound in related stocks. The market reaction was mixed, with some viewing the virus as a significant threat while others downplayed its impact, comparing it to previous outbreaks like Ebola [11][12]. - Stocks such as Da'an Gene and Cap Bio experienced significant volatility, with Cap Bio achieving a two-day limit up. However, other related stocks like Shuoshi Bio and New Ganges saw substantial declines [14][20]. - A report from the Wuhan Institute of Virology indicated that the oral nucleoside drug VV116 showed high efficacy against the Nipah virus, which positively impacted related stocks like Junshi Biosciences [16][17]. ETF Activity - The market saw a rapid decline in the three major indices, with a strong overall loss effect. However, a rebound occurred in the afternoon, coinciding with increased trading volumes in ETFs such as the CSI 1000 ETF and the SSE 50 ETF, suggesting a potential correlation between ETF activity and market performance [23]. Tian Di Online - Tian Di Online opened lower but quickly rebounded to hit the daily limit, marking its second consecutive limit up. The stock has surged nearly 50% over the past seven trading days, driven by its association with the live-streaming concept linked to Li Yapeng [26][27].

Group 1 - The recent outbreak of Nipah virus in West Bengal, India, has led to 5 confirmed cases, with one patient in critical condition, prompting enhanced preventive measures in neighboring countries like Thailand and Nepal [1] - Nearly 100 individuals have been placed under home quarantine, and infected patients are receiving treatment in hospitals in Kolkata and surrounding areas [1] - The Nipah virus is a zoonotic virus that can be transmitted from infected animals to humans, with symptoms including acute respiratory infections and potentially fatal encephalitis, and there is currently no approved vaccine or specific treatment available [1][4] Group 2 - The stock prices of vaccine and in vitro diagnostic (IVD) sectors surged following the news, with companies like Hualan Biological (301207) and Jindike experiencing significant gains, reaching their daily limit [1][2] - The vaccine index rose by 6.60%, with notable increases in stock prices for companies such as Hualan Vaccine (20.00%), Jindike (19.98%), and Zhifei Biological (14.87%) [2] - The market response indicates a heightened interest in companies involved in vaccine development and diagnostic testing related to the Nipah virus [1][8] Group 3 - Nipah virus is classified as a high-pathogenicity pathogen with a mortality rate ranging from 40% to 75%, and it has been recognized as a significant public health threat for over 25 years [3][5] - The virus's natural reservoir is fruit bats, which can transmit the virus through contaminated food or environments, and outbreaks have primarily occurred in South and Southeast Asia [3][5] - Current detection methods include antibody and nucleic acid testing, with companies like Zhijiang Biological and Daan Gene developing specific test kits for Nipah virus detection [6][7] Group 4 - Companies are actively developing testing solutions, with Zhijiang Biological's Nipah virus PCR test kit achieving high sensitivity and rapid results, and Daan Gene's kit also showing promising detection capabilities [7] - Research into vaccines for Nipah virus is ongoing, with some candidates entering clinical trials, and monoclonal antibodies showing potential in compassionate use [8] - The stock prices of companies involved in vaccine development, such as Watson Bio, Zhifei Bio, and Hualan Vaccine, have seen increases, reflecting investor optimism regarding potential solutions to the Nipah virus threat [8]

Group 1 - Institutional trading today featured 55 stocks, with 26 seeing net purchases and 29 experiencing net sales [1] - The top three stocks with the highest institutional purchases were: DingTong Technology (9.13 billion), QianZhao Optoelectronics (4.15 billion), and WangSu Technology (2.18 billion) [1] - DingTong Technology saw a price increase of 6.96%, while QianZhao Optoelectronics rose by 8.55% [2] Group 2 - WangSu Technology had a net purchase of 2.18 billion from three institutions [3] - Amazon Web Services (AWS) recently raised its EC2 machine learning capacity block prices by approximately 15%, indicating a significant shift in cloud computing pricing logic amid AI resource shortages [3] - The subsidiary Aijie Cloud offers a one-stop service for GPU and CPU cloud computing rental [3] Group 3 - The Nipah virus outbreak in West Bengal, India, has been reported [3] - Zhijiang Biology has received EU CE certification for its Nipah virus nucleic acid testing kit [3] - On January 26, spot silver surpassed 100 dollars per ounce, and spot gold exceeded 5000 dollars per ounce [3]